NOT-DA-14-052: Notice of Participation of the National Institute on Drug Abuse in PA-14-334 "Advancing Interventions to Improve Medication Adherence (R01)"

Notice of Participation of the National Institute on Drug Abuse in PA-14-334 "Advancing Interventions to Improve Medication Adherence (R01)"

Notice Number:

NOT-DA-14-052

Key Dates

Release Date: October 17, 2014

Related Announcements

PA-14-334

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse's participation, effective immediately, in PAR-14-334 "Advancing Interventions to Improve Medication Adherence (R01)."

The following sections of PAR-14-334 have been updated to reflect the participation of NIDA in this FOA.

Part 1. Overview Information

Components of Participating Organizations

Office of Behavioral and Social Sciences Research (OBSSR)
National Cancer Institute (NCI)
National Eye Institute (NEI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Mental Health (NIMH)
National Center for Complementary and Alternative Medicine (NCCAM)
National Institute of Nursing Research (NINR)
National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.399, 93.867, 93.837, 93.173, 93.847, 93.242, 93.361, 93.213, 93.273, 93.395, 93.393, 93.273

Part 2. Section I. Research Objective

The National Institute on Drug Abuse seeks research involving medication adherence interventions for any substance abusing population or populations with chronic pain; research aimed at generating, refining, feasibility testing, or pilot testing adherence interventions for use in substance abuse treatment and primary care; research to technologically enhance adherence interventions in substance abusing populations; research to modify interventions to promote improved adherence to medical treatment regimens in HIV+ drug users.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Will M. Aklin, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-3207
Email: aklinwm@nida.nih.gov

Financial/Grants Management Contact(s)

Carol Alderson
National Institute on Drug Abuse (NIDA)
Telephone: 301-933-6196
Email: aldersoc@nida.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Will M. Aklin, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-3207
Email: aklinwm@nida.nih.gov